A case report of dopa-responsive dystonia. 2001

X Tang, and Y Li
Department of Neurology, PUMC Hospital, CAMS & PUMC, Beijing 100730.

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004421 Dystonia An attitude or posture due to the co-contraction of agonists and antagonist muscles in one region of the body. It most often affects the large axial muscles of the trunk and limb girdles. Conditions which feature persistent or recurrent episodes of dystonia as a primary manifestation of disease are referred to as DYSTONIC DISORDERS. (Adams et al., Principles of Neurology, 6th ed, p77) Muscle Dystonia,Dystonia, Diurnal,Dystonia, Limb,Dystonia, Paroxysmal,Diurnal Dystonia,Dystonia, Muscle,Limb Dystonia,Paroxysmal Dystonia
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000978 Antiparkinson Agents Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. Antiparkinson Drugs,Antiparkinsonian Agents,Antiparkinsonians,Agents, Antiparkinson,Agents, Antiparkinsonian,Drugs, Antiparkinson
D001545 Benserazide An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone. Serazide,Seryltrihydroxybenzylhydrazine,DL-Serine 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide,Ro 4-4602,Seryltrihydroxy Benzylhydrazine,Benzylhydrazine, Seryltrihydroxy,Ro 4 4602,Ro 44602

Related Publications

X Tang, and Y Li
January 2013, Journal of insurance medicine (New York, N.Y.),
X Tang, and Y Li
June 1995, Singapore medical journal,
X Tang, and Y Li
June 2023, Clinical neurology and neurosurgery,
X Tang, and Y Li
December 1993, Arquivos de neuro-psiquiatria,
X Tang, and Y Li
January 1988, Advances in neurology,
X Tang, and Y Li
May 1989, BMJ (Clinical research ed.),
X Tang, and Y Li
March 2010, BMJ (Clinical research ed.),
X Tang, and Y Li
August 1995, Current opinion in neurology,
X Tang, and Y Li
January 2009, Vojnosanitetski pregled,
X Tang, and Y Li
November 2018, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
Copied contents to your clipboard!